Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT03493854 Completed - Early Breast Cancer Clinical Trials

A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Subcutaneous Administration of the Fixed-Dose Combination of Pertuzumab and Trastuzumab in Combination With Chemotherapy in Participants With HER2-Positive Early Breast Cancer

FeDeriCa
Start date: June 14, 2018
Phase: Phase 3
Study type: Interventional

This is a global Phase III, two-arm, open-label, multicenter, randomized study to investigate the pharmacokinetics, efficacy, and safety of the fixed-dose combination (FDC) of pertuzumab and trastuzumab for subcutaneous (SC) administration in combination with chemotherapy in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer in the neoadjuvant/adjuvant setting.

NCT ID: NCT03491917 Completed - Breast Cancer Clinical Trials

Fujifilm DBT Plus S-View Versus FFDM Alone in the Detection of Breast Cancer

Start date: November 3, 2017
Phase:
Study type: Observational

The purpose of this pilot is to provide credible performance estimate information in order to conduct a subsequent pivotal reader study.

NCT ID: NCT03487601 Completed - Breast Cancer Clinical Trials

Transcranial Direct Current Stimulation (tDCS) to Improve Fatigue and Cognitive Function

Start date: December 12, 2017
Phase: N/A
Study type: Interventional

This research is being done to determine whether transcranial direct current stimulation (tDCS) can improve fatigue and certain thinking skills in women with breast cancer receiving chemotherapy. Transcranial Direct Current Stimulation is a form of brain stimulation during which low amounts of electrical current are delivered to the brain using electrodes attached to the scalp. The idea of using electrical stimulation to affect neurological symptoms has been around for more than 100 years with the first reported use in 1801. Since the 1960s, tDCS has been used in research for a variety of reasons including stroke rehabilitation, memory enhancement and for depression. People aged 18 or older who are currently receiving chemotherapy with docetaxel and who are experiencing fatigue may join.

NCT ID: NCT03482401 Completed - Breast Cancer Clinical Trials

Disposition of Dietary Polyphenols and Methylxanthines in Mammary Tissues From Breast Cancer Patients

POLYSEN
Start date: June 1, 2017
Phase: N/A
Study type: Interventional

The aim is to characterise the metabolic profiling of dietary polyphenols in normal and malignant breast tissues from breast cancer patients.

NCT ID: NCT03481998 Completed - Clinical trials for Advanced Breast Cancer

A Study of SHR6390 in Combination With Letrozole or Anastrozole or Fulvestrant in Patients With HR Positive and HER2 Negative Advanced Breast Cancer

Start date: March 22, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase IB/II clinical trial to evaluate the efficacy and safety of SHR6390 in combination with Letrozole or Anastrozole or Fulvestrant. Patients who have HR positive and HER2 negative recurrent/metastatic breast cancer and have not received systemic anticancer therapy are eligible for study.

NCT ID: NCT03479385 Completed - Breast Cancer Clinical Trials

Integrative Approaches to Cancer Survivorship: Project 3

IACS2
Start date: April 17, 2018
Phase: N/A
Study type: Interventional

The purpose of this study is to conduct a randomized controlled trial or RCT of the following 2 supportive care interventions in recent breast cancer survivors: an Integrative Medicine intervention based on Ayurvedic medicine and a Health Education intervention.

NCT ID: NCT03478384 Completed - Breast Cancer Clinical Trials

Self-efficacy Coaching for Women With Breast Cancer

SECOM-PSWE
Start date: March 16, 2018
Phase: N/A
Study type: Interventional

This is an open, prospective, multi-center, interventional study to evaluate the benefit and efficacy of individualized self-efficacy coaching for women with high-risk early breast cancer. In total, 6 sites will be assigned 1:1 to either the experimental arm (Group A) or the control arm (Group B). The controlled site assignment will assure a balanced site-specific QoL between both groups at baseline. All patients will be medically treated according to guidelines. The experimental Group A will in addition receive regular self-efficacy coaching.

NCT ID: NCT03477396 Completed - HER2/Neu Negative Clinical Trials

Ribociclib and Aromatase Inhibitor in Treating Older Participants With Hormone Receptor Positive Metastatic Breast Cancer

Start date: June 14, 2018
Phase: Phase 2
Study type: Interventional

This phase IIA trial studies the side effects of ribociclib and aromatase inhibitor and how well they work in treating participants with hormone receptor positive breast cancer that has spread to other places in the body. Ribociclib and aromatase inhibitors may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03477019 Completed - Breast Neoplasms Clinical Trials

Ultrasound-enhanced Delivery of Chemotherapy to Patients With Liver Metastasis From Breast- and Colorectal Cancer

Start date: November 12, 2018
Phase: Phase 1/Phase 2
Study type: Interventional

The aim of this clinical trial is to investigate whether the therapeutic response of chemotherapy can be improved by focused ultrasound and microbubbles. Patients with liver metastases from breast cancer and colorectal cancer will be included. Computer Tomography (CT) will be performed as a baseline scan before treatment start. Two metastases in each patients liver will be preselected and randomized to either "target lesion" to be treated or "control lesion" to serve as internal control. The patients will receive conventional treatment with chemotherapy according to national guidelines. After intravenous chemotherapy infusion the patients will receive the experimental treatment. The target lesion will get focused ultrasound (FUS). Simultaneously repeated bolus-doses of microbubbles will be administered intravenously. The investigators will measure the difference in response between FUS- treated and -untreated lesions on the post-treatment CT scan.

NCT ID: NCT03476226 Completed - Breast Cancer Clinical Trials

Cognitive Dysfunction and Breast Cancer Coping Strategies Impact on QOL

Start date: November 18, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether patients experience a better quality of life when they have received education about coping strategies for cognitive dysfunction.